Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

• Príomhchruthaitheoirí: Stephanie F. Ling (Údar), Kayode Ogungbenro (Údar), Adam S. Darwich (Údar), Amirah Binti Mohammad Ariff (Údar), Nisha Nair (Údar), James Bluett (Údar), Ann W. Morgan (Údar), John D. Isaacs (Údar), Anthony G. Wilson (Údar), Kimme L. Hyrich (Údar), Anne Barton (Údar), Darren Plant (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2024-05-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Efficacy to biologics in rheumatoid arthritis (RA) patients is variable and is likely influenced by each patient's circulating drug levels. Using modelling and simulation, the aim of this study was to investigate whether adalimumab and etanercept biosimilar dosing intervals can be altered to ac...